A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/22/2006	EP1723120A1 Ion channel modulators
11/22/2006	EP1723119A1 Ion channel modulators
11/22/2006	EP1723116A2 Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
11/22/2006	EP1723115A1 Biphenyl compounds useful as muscarinic receptor antagonists
11/22/2006	EP1723114A1 Biphenyl compounds useful as muscarinic receptor antagonists
11/22/2006	EP1723113A1 Biphenyl compounds useful as muscarinic receptor antagonists
11/22/2006	EP1723112A1 Biphenyl compounds useful as muscarinic receptor antagonists
11/22/2006	EP1723111A1 Biphenyl compounds useful as muscarinic receptor antagonists
11/22/2006	EP1723110A1 Biphenyl compounds useful as muscarinic receptor antagonists
11/22/2006	EP1723109A1 Biphenyl compounds useful as muscarinic receptor antagonists
11/22/2006	EP1723108A1 Biphenyl compounds useful as muscarinic receptor antagonists
11/22/2006	EP1723105A1 Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
11/22/2006	EP1723104A2 Sulfur-containing compositions and processes for making same
11/22/2006	EP1723102A2 N-substituted benzene sulfonamides
11/22/2006	EP1723100A2 Terephthalamide peptidomimetic compounds and methods
11/22/2006	EP1723097A1 Ester derivatives of rhein and their therapeutic use
11/22/2006	EP1723096A2 Structured triglycerides and emulsions comprising same
11/22/2006	EP1722857A2 Use of a compound having two gold(i) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(i) atoms for the treatment of cancer
11/22/2006	EP1722856A1 Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin d3 for the prophylaxis of bone diseases
11/22/2006	EP1722855A1 Of at use of an antagonist compound of at least one receptor selected from a group comprising beta-adrenergic receptors, a at1, 5-ht5 and galanin receptor for preparing a pharmaceutical composition for treating rosacea
11/22/2006	EP1722826A2 Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
11/22/2006	EP1722823A2 Pharmaceutical composition
11/22/2006	EP1722821A1 Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
11/22/2006	EP1722817A1 Antineoplastic combinations of cci-779 and rituximab
11/22/2006	EP1722800A1 A medical solution, a method for producing said medical solution and use thereof
11/22/2006	EP1722799A2 Treatment of pulmonary artery hypertension with dhea, dheas, dhea analogs or dhea derivatives
11/22/2006	EP1722798A1 Pyrimidine compounds as purine receptor antagonist
11/22/2006	EP1722797A1 Isoquinoline derivatives and methods of use thereof
11/22/2006	EP1722796A2 Tetracyclic lactam derivatives and uses thereof
11/22/2006	EP1722795A1 Piperidinyl prostaglandin e analogs
11/22/2006	EP1722794A1 Methods and compositions for the treatment of conditions related to gastric acid secretion
11/22/2006	EP1722793A1 Bicyclic modulators of androgen receptor function
11/22/2006	EP1722792A1 Selected cgrp-antagonists, method for the production and use thereof as medicaments
11/22/2006	EP1722791A2 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
11/22/2006	EP1722790A2 Novel bicyclic compounds as modulators of androgen receptor function and method
11/22/2006	EP1722789A2 Therapeutic modulation of ppar (gamma) activity
11/22/2006	EP1722788A2 Ion channel modulators
11/22/2006	EP1722787A1 Ion channel modulators
11/22/2006	EP1722786A2 Ion channel modulators
11/22/2006	EP1722785A1 Ion channel modulators
11/22/2006	EP1722784A2 Ion channel modulators
11/22/2006	EP1722783A2 Ion channel modulators
11/22/2006	EP1722782A2 Compounds, compositions and methods for inhibiting or treating hiv-1
11/22/2006	EP1722781A2 Maleiimide anti-tumor phosphatase inhibitors
11/22/2006	EP1722780A1 A method of preventing or treating glaucoma
11/22/2006	EP1722779A1 Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents
11/22/2006	EP1722778A1 Methods and compositions for the treatment of lipodystrophy
11/22/2006	EP1722777A2 Use of beta-lapachone for the treatment of pancreatic cancer
11/22/2006	EP1722776A2 Use of beta-lapachone as a broad spectrum anti-cancer agent
11/22/2006	EP1722775A1 Use of beta-lapachone for treating hematologic tumors
11/22/2006	EP1722774A1 Use of a compound modifying an interleukin 5, interleukin 6 and/or interleukin 10 secretion for preparing a pharmaceutical composition for rosacea treatment
11/22/2006	EP1722773A1 Pregabalin composition
11/22/2006	EP1722772A1 Dietary supplementation with stoichiometrically specific potassium magnesium citrate
11/22/2006	EP1722771A1 Compositions and methods for preventing or treating an inflammatory response
11/22/2006	EP1722770A1 Use of metformin and orlistat for the treatment of prevention of obesity
11/22/2006	EP1722769A2 Methods for altering insulin secretion
11/22/2006	EP1722768A2 Medicaments for treating barrett's oesophagus
11/22/2006	EP1722767A2 NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
11/22/2006	EP1722766A2 Management of ophthalmologic disorders, including macular degeneration
11/22/2006	EP1722765A2 Osteoblast factor(s) that regulates human prostate cancer migration to and invasion of bone
11/22/2006	EP1722764A1 Methods for relief of pain
11/22/2006	EP1722762A2 Nanocell drug delivery system
11/22/2006	EP1722759A2 Chitosan containing solution
11/22/2006	EP1722758A1 Chronotherapeutic compositions and methods of their use
11/22/2006	EP1722714A1 Biocompatible polymeric delivery systems for sustained release of quinazolinones
11/22/2006	EP1722645A1 Solubilized coq-10 and carnitine
11/22/2006	EP1722630A2 Compositions and methods of treatment for inflammatory diseases
11/22/2006	EP1651644B1 Substituted thiazole-benzoisothiazole dioxide derivatives, method for the production thereof and use of the same
11/22/2006	EP1635817B1 1-phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases
11/22/2006	EP1599205B1 Pten inhibitor or maxi-k channels opener
11/22/2006	EP1572715B1 Steroid compounds with anti-tumor activity
11/22/2006	EP1572673B1 Antioxidant from natural source
11/22/2006	EP1558080A4 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
11/22/2006	EP1554243B1 Bicyclic benzamide compounds as histamine h3 receptor ligand useful in the treatment of neurological diseases
11/22/2006	EP1551860B1 Glucocorticoid receptor ligands for the treatment of metabolic disorders
11/22/2006	EP1539184B1 Estrogen replacement regimen
11/22/2006	EP1534265B1 Combination of an aromatase inhibitor with a bisphosphonate
11/22/2006	EP1532129B1 Sorbicillactone-a derivatives for the treatment of tumour and viral diseases
11/22/2006	EP1530574B1 Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments
11/22/2006	EP1511770B1 Glycoprotein vi-fc fusion protein for the treatment of vascular diseases
11/22/2006	EP1509520B1 Use of benzo(c)quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction
11/22/2006	EP1501815B1 Substituted phenylacetamides and their use as glucokinase activators
11/22/2006	EP1501798A4 SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS
11/22/2006	EP1497291B1 Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
11/22/2006	EP1483271B1 Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
11/22/2006	EP1483265B1 Purine derivatives as kinase inhibitors
11/22/2006	EP1480620B1 (ester)-lysolecithins in liposomes
11/22/2006	EP1476196B1 Oral solid solution formulation of a poorly water-soluble active substance
11/22/2006	EP1474131B1 Use of anethole dithiolethione in lung cancer chemoprevention
11/22/2006	EP1467982B1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
11/22/2006	EP1461034B1 Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines
11/22/2006	EP1458721B1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
11/22/2006	EP1458683B1 Heteroaryl-substituted aminocyclohexane derivatives
11/22/2006	EP1454905B1 Novel substance fki-1083 and process for producing the same
11/22/2006	EP1438055A4 D-tagatose as an anti-biofilm agent
11/22/2006	EP1438049B1 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
11/22/2006	EP1432402B1 Compositions for delivery of drug combinations
11/22/2006	EP1429756B1 Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
11/22/2006	EP1427717B1 Bioprecursors for percutaneous application
11/22/2006	EP1423131B1 Calcium trifluoroacetate with cytotoxic activity

1 ... 3998 3999 4000 4001 4002 4003 4004 4005 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 4017 4018 ... 7860